Genes and environment: a moving target? Studies from multiple populations have shown shifts of the typical HLA class II gene associations during the last few decades. Indeed, fewer patients carry the high risk heterozygous HLA-DR/DQ genotype, except among younger children [59–63], in whom the disease is becoming more common [4]. In contrast, more patients now carry moderate risk HLA types and genotypes. Such shifts in HLA associations may be explained by stronger environmental pressures that enhance HLA-mediated genetic predisposition and/or broaden the spectrum of diabetogenic gene–environment interactions. Viruses, and especially enteroviruses, rank at the top of the list of environmental factors that have been linked to T1DM.

In this Exclusive Interview transcript, Tracey Brown talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the start of her journey to working toward a diabetes cure, becoming CEO of the ADA, and her vision for the ADA.

In this Exclusive Interview, Tracey Brown talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the start of her journey to working toward a diabetes cure, becoming CEO of the ADA, and her vision for the ADA.

In part 1 of this Exclusive Interview, Tracey Brown shares her epiphany as a person with type 2 diabetes in a conversation with Diabetes in Control Publisher Steve Freed.

In part 2 of this Exclusive Interview, Tracey Brown explains her varied stops along her road to becoming the CEO of the ADA in a conversation with Diabetes in Control Publisher Steve Freed.

In part 3 of this Exclusive Interview, Tracey Brown talks with Diabetes in Control Publisher Steve Freed about her vision for the ADA and the need to educate and increase awareness.

In part 4, the conclusion of this Exclusive Interview, Tracey Brown talks with Diabetes in Control Publisher Steve Freed about her disease management and reaching others to manage their diabetes as well.

Fracture risk up with T2DM and current use of rosiglitazone, pioglitazone regardless of glycemic control

Every time the ADA or ACE updates their guidelines, the position and order of glucose-lowering medications changes. Although year after year metformin is the #1 choice, the second and third choices become more ambiguous and it seems that any order is possible. including early basal insulin use. The selection is …

The best and most affordable treatment for type 2 diabetes